In this video, Catherine S. Diefenbach, MD, discusses the differences between three FDA-approved CD19-directed chimeric antigen receptor T-cell therapy products for the treatment of lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback